Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Interferon alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Interferon alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Interferon alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer Clinical research trials and Interferon alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Interferon alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer. Interferon alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Interferon alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Interferon alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.

Home > "I" Clinical Trials Conditions > Interferon alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer

Interferon alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer



Interferon alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer

For Condition: stage 4 renal cell cancer
Status: Recruiting
Sponsor(s): Cancer Research UK ,
Synopsis: RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. It is not yet known if interferon alfa is more effective with or without thalidomide in treating metastatic kidney cancer. PURPOSE: Randomizedphase II trial to compare the effectiveness of interferon alfa with or without thalidomide in treating patients who have metastatic kidney cancer.
Details: OBJECTIVES: - Determine the safety of interferon alfa and thalidomide in patients with metastatic renal cell carcinoma. - Compare the relative toxicity of interferon alfa with or without thalidomide in these patients. - Assess the antiangiogenic effect of thalidomide by monitoring the angiogenesis-associated factors in these patients. - Compare, in a preliminary manner, the efficacy of interferon alfa with or without thalidomide in these patients. - Compare the quality of life of patients treated with these regimens. OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two treatment arms. - Arm I: Patients receive interferon alfa subcutaneously 3 times a week and oral thalidomide once daily for 12 weeks. - Arm II: Patients receive interferon alfa only as in arm I. Treatment in both arms repeats every 12 weeks in the absence of disease progression or unacceptable toxicity. Patients in arm II who develop disease progression discontinue interferon alfa and receive thalidomide only as in arm I. Quality of life is assessed at baseline and then every 3 weeks during each study course. PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed metastatic renal cell carcinoma - Measurable progressive disease, defined as non-irradiated marker lesions greater than 1 cm PATIENT CHARACTERISTICS: Age: - Over 18 Performance status: - WHO 0-2 Life expectancy: - More than 12 weeks Hematopoietic: - Neutrophil count greater than 1,500/mm^3 - Platelet count greater than 100,000/mm^3 - Hemoglobin greater than 10 g/dL Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - AST/ALT less than 5 times ULN Renal: - Creatinine clearance greater than 50 mL/min OR - Edetic acid clearance greater than 40 mL/min Cardiovascular: - No unstable angina or myocardial infarction within the past 6 months Other: - No other prior invasive malignancy except cervical intraepithelial neoplasia or nonmelanomatous skin cancer - No chronic neurological disease causing peripheral neuropathy - No diabetes mellitus - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use at least one highly effective method and at least one additional effective method of contraception for female patients and barrier contraception for male patients for at least 2 weeks before and during study PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior interferon alfa for metastatic renal cell carcinoma Chemotherapy: - No prior systemic chemotherapy for metastatic renal cell carcinoma - No concurrent cytotoxic therapy Endocrine therapy: - No concurrent corticosteroids Radiotherapy: - See Disease Characteristics - Concurrent local radiotherapy for symptomatic secondary sites of disease allowed if these sites are not being used as markers of disease response Surgery: - Not specified Other: - No other prior systemic treatment for metastatic renal cell carcinoma - No concurrent chronic medication known to cause peripheral neuropathy
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
AdrianHarris,  Study Chair,  Oxford Radcliffe Hospital

St. James's University Hospital *Recruiting*
Leeds,  England,  LS9 7TF
United Kingdom
Recruiting Peter  Selby 113 242 98 83

Beatson Oncology Centre *Recruiting*
Glasgow,  Scotland,  G11 6NT
United Kingdom
Recruiting Paul  Vasey 0141-211-2009

Oxford Radcliffe Hospital *Recruiting*
Oxford,  England,  0X3 9DU
United Kingdom
Recruiting Adrian  Harris 44-1865-226-184


Additional Information:
Study ID Numbers:  CDR0000069055;  ICRF-C00.204,EU-20129
Study Start Date: 
Record last reviewed: December 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00027664

Other Stage 4 Renal Cell Cancer Studies:
1. SU5416 and Interferon alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

2. Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer

3. Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer

4. Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer

5. Interferon alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Related Studies:

Other stage 4 renal cell cancer Clinical Trials
Other England Clinical Trials
Other Oxford Clinical Trials

Interferon alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer
Modify your Search

  Other stage 4 renal cell cancer Clinical Trials
  Other England Clinical Trials
  Other Oxford Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103